Abstracts tagged "Pediatric rheumatology"

Abstract Number: 1686 • ACR Convergence 2023
Adolescent and Young Adult Rheumatology Patient Reports of Reproductive Health Screening and Counseling in the Clinical Setting
Brittany Huynh¹, Mary Ott¹ and Stacey Tarvin², ¹Indiana University School of Medicine, Indianapolis, IN, ²Riley Hospital for Children at Indiana University Health, Indianapolis, IN
Background/Purpose: Adolescents and young adults (AYAs) with rheumatic disease are at high risk of poor reproductive health outcomes due to disease-related risks and teratogen use.…
Abstract Number: 2050 • ACR Convergence 2023
Variability in Vaccination Practices in Children with Rheumatic Diseases: Results of a Rheumatology Provider Childhood Arthritis and Rheumatology Research Alliance (CARRA)-wide Survey
Randal De Souza¹, Merav Heshin Bekenstein², Beth Rutstein³, Maria Schletzbaum⁴, Nora Singer⁵, Melanie Kohlheim⁶, vincent del gaizo⁷, Kelly Wise⁸, Melica Nikahd⁹, Guy Brock¹⁰, Rebecca Sadun¹¹, Monica Ardura¹, Vidya Sivaraman¹ and For The CARRA Registry Investgators⁷, ¹Nationwide Children's Hospital, Columbus, OH, ²Dana Children's Hospital of Tel Aviv Medical Center, Tel Aviv, Israel, ³Division of Rheumatology at Children's Hospital of Philadelphia, Philadelphia, PA, ⁴St. Louis Children’s Hospital / Washington University in St. Louis, Middleton, WI, ⁵The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH, ⁶Self, Granville, OH, ⁷CARRA, Inc, Washington, DC, ⁸Nationwide Children's Hospital, Hilliard, OH, ⁹Ohio State University, Columbus, OH, ¹⁰Dept. of Biomedical Informatics, Columbus, OH, ¹¹Duke University, Durham, NC
Background/Purpose: Immunocompromised children (ICC), including children with rheumatic diseases receiving immunosuppressive therapies (IST) are at increased risk of morbidity from vaccine-preventable infections. The 2022 American…
Abstract Number: 2476 • ACR Convergence 2023
Defining Cutoffs for Disease Activity States in Systemic Juvenile Idiopathic Arthritis Based on the Systemic Juvenile Arthritis Disease Activity Score
Silvia Rosina¹, Ana Isabel Rebollo Gimenez², Letizia Tarantola¹, Yulia Vyzhga¹, Luca Carlini³, Elisa Patrone⁴, Maria Katsikas⁵, Claudia Saad-Magalhaes⁶, Dalia El-Ghoneimy⁷, Yasser El Miedany⁸, Raju Khubchandani⁹, Priyankar Pal¹⁰, Gabriele Simonini¹¹, Giovanni Filocamo¹², Maurizio Gattinara¹³, Fabrizio De Benedetti¹⁴, Davide Montin¹⁵, Adele Civino¹⁶, Muatasem Alsuweiti¹⁷, Valda Stenevicha¹⁸, Vyacheslav Chasnyk¹⁹, Ekaterina Alexeeva²⁰, Sulaiman Al-Mayouf²¹, Soamarat Vilayuk²², Angela Pistorio²³ and Angelo Ravelli²⁴, ¹IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Autoinfiammatorie, Genova, Italy, ²IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy, ³IRCCS Istituto Giannina Gaslini, UOC Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, Genoa, Italy, ⁴IRCCS Istituto Giannina Gaslini, UOC Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, Genova, Italy, ⁵Hospital de Pediatria Juan P Garrahan, Servicio de Inmunologia/Reumatologia, Buenos Aires, Argentina, ⁶Sao Paulo State University, Botucatu, Brazil, ⁷PAIR Unit, Children's Hospital Ain Shams University, Cairo, Egypt, ⁸Ain Shams University, Italian Hospital St Abbassia, Cairo, Egypt, ⁹SRCC Childrens Hospital, Mumbai, India, ¹⁰Institute of Child Health, Pediatric Medicine, Kolkata, India, ¹¹Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence Italy. NeuroFARBA Department, University of Florence, Florence, Italy, ¹²Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Pediatric Rheumatology, Milan, Italy, ¹³Istituto Gaetano Pini, Divisione di Reumatologia, Milan, Italy, ¹⁴Bambino Gesu Children's Hospital, Division of Rheumatology, Rome, Italy, ¹⁵Immunology and Rheumatology Unit, Regina Margherita Children Hospital, Turin, Italy, ¹⁶P.O. Vito Fazzi, Uo Pediatria - Sezione Reumatologia e Immunologia Pediatrica, Lecce, Italy, ¹⁷King Hussein Medical Center, Department of Pediatrics, Amman, Jordan, ¹⁸Department of Paediatrics, Riga Stradins University, Children University Hospital, Riga, Latvia, ¹⁹Saint-Petersburg State Pediatric Medical University, Pediatrics, Saint-Petersburg, Russia, ²⁰Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, ²¹King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, ²²Mahidol University Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand, ²³Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ²⁴Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: The systemic Juvenile Arthritis Disease Activity Score (sJADAS) is a composite disease activity (DA) score specifically validated for use in systemic JIA (sJIA), whose…
Abstract Number: 0350 • ACR Convergence 2023
Presentation, Management, and Outcomes of Systemic JIA-Associated Lung Disease: A Single Center Experience
Ana Luiza Altaffer¹, Maria Pereira², Marietta De Guzman² and Andrea Ramirez², ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Houston, TX
Background/Purpose: Interstitial lung disease (ILD) is a rare and severe complication of systemic juvenile idiopathic arthritis (SJIA) that was recognized relatively recently, and its incidence…
Abstract Number: 0372 • ACR Convergence 2023
Efficacy and Safety of Secukinumab in Juvenile Idiopathic Arthritis: Interim Results from the Extension of the JUNIPERA Trial
Hermine Brunner¹, Ivan Foeldvari², Ekaterina Alexeeva³, Nuray Aktay Ayaz⁴, Grant Schulert⁵, Seza Ozen⁶, Artem Popov⁷, Athimalaipet V Ramanan⁸, Christiaan Scott⁹, Betul Sozeri¹⁰, Elena Zholobova¹¹, Sudhanshu Chakraborty¹², Xuan Zhu¹³, Ruvie Martin¹³, Sarah Whelan¹⁴, Sharonjeet Kaur¹⁵, Luminita Pricop¹³, Daniel J Lovell¹⁶, Alberto Martini¹⁷ and Nicolino Ruperto¹⁸, ¹Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ²Hamburger Zentrum fuer Kinder und Jugendrheumatologie, Rheumatology, Hamburg, Germany, ³National Scientific and Practical Center of Children's Health, Rheumatology, Moscow, Russia, ⁴Department of Pediatric Rheumatology, Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Hacettepe University Medical Faculty, Ankara, Turkey, ⁷Ural State Medical University Ekaterinburg, Sverdlovsk, Russia, ⁸Bristol Royal Hospital for Children & Translational Health Sciences, University of Bristol, Bristol, United Kingdom, ⁹Department of Paediatric Rheumatology, Red Cross War Memorial Children’s Hospital, University of Cape Town, Cape Town, South Africa, ¹⁰Division of Pediatric Rheumatology, University of Health Sciences, Ümraniye Training and Research Hospital, Istanbul, Turkey, ¹¹First Moscow State Medical University, n.a. I.M.Sechenov, Moscow, Russia, ¹²IQVIA, Durrham, NC, ¹³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁴Novartis Ireland Ltd, Dublin, Ireland, ¹⁵Novartis Pharma AG, Basel, Switzerland, ¹⁶UC Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, OH, ¹⁷Università di Genova, Genova, Italy, ¹⁸IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy
Background/Purpose: Secukinumab has demonstrated efficacy and safety in patients with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) categories of juvenile idiopathic arthritis (JIA) for…
Abstract Number: 0918 • ACR Convergence 2023
Network Analysis of Genome Sequences Identifies Important Pathways in the Pathogenesis of Childhood-onset Systemic Lupus Erythematosus
Katie Heitzman¹, Sneha Dass¹, Linda Hiraki², Earl Silverman³, Christiaan Scott⁴, Ana Barrera-Vargas⁵, Zuoming Deng⁶, Mariana Kaplan⁷, Luis Franco⁸ and Laura Lewandowski⁹, ¹Lupus Genetics and Global Health Disparities Unit, Systemic Autoimmunity Branch, NIAMS, Bethesda, MD, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Silverman, Toronto, ON, Canada, ⁴Paediatric Rheumatology, Red Cross War Memorial Children’s Hospital and University of Cape Town, Cape Town, South Africa, ⁵Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁷Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH); Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ⁸Functional Immunogenomics Section, Systemic Autoimmunity Branch, NIAMS, NIH, Bethesda, MD, ⁹Lupus Genetics and Global Health Disparities Unit, Systemic Autoimmunity Branch, NIAMS, NIH, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disorder. The pathogenesis of SLE is not fully understood, but high twin/sibling concordance rates suggest…
Abstract Number: 1232 • ACR Convergence 2023
Improvement Across Organ System, Physician and Patient Reported Outcome Measures over a 36-time Period in the Juvenile Systemic Scleroderma Inception Cohort
Ivan Foeldvari¹, Jens Klotsche², Ozgur Kasapcopur³, Amra Adrovic⁴, Kathryn Torok⁵, Brian Feldman⁶, Maria Teresa TErreri⁷, Ana Sakamoto⁸, Jordi Anton⁹, Simone Appenzeller¹⁰, Edoardo Marrani¹¹, Maria Katsikas¹², Maria Jose Santos¹³, FLAVIO SZTAJNBOK¹⁴, Lillemor Berntson¹⁵, Juergen Brunner¹⁶, Sindhu Johnson¹⁷, Mikhail Kostik¹⁸, Kirsten Minden¹⁹, Farzana Nuruzzaman²⁰ and Nicola Helmus²¹, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁴Istanbul University - Cerrahpasa, Istanbul, Turkey, ⁵University of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷UNIFESP, São Paulo, Brazil, ⁸Federal University of São Paulo (UNIFESP), São Paulo, Brazil, ⁹Hospital Sant Joan de Déu, Pediatric Rheumatology Department, Universitat de Barcelona, Barcelona, Spain, ¹⁰UNICAMP, Campinas, Brazil, ¹¹University of Florence, Firenze, Italy, ¹²Hospital de Pediatria Juan P Garrahan, Servicio de Inmunologia/Reumatologia, Buenos Aires, Argentina, ¹³Hospital Garcia de Orta, Almada, Lisboa, Portugal, ¹⁴UFRJ/UERJ, São Paulo, Brazil, ¹⁵Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ¹⁶Medical University Innsbruck; Department of Pediatrics, Pediatric Rheumatology, Innsbruck, Austria, ¹⁷Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ¹⁸Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ¹⁹Charité University Medicine and German Rheumatism Research Center Berlin, Berlin, Germany, ²⁰Stony Brook Children's Hospital, Stony Brook, NY, ²¹Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1, 000, 000 children. The Juvenile Systemic Scleroderma Inception cohort…
Abstract Number: 1252 • ACR Convergence 2023
Physician Global Assessment of Disease Activity in Childhood-Onset Systemic Lupus Erythematosus – Does the Approach Matter?
Ekemini Ogbu¹, Hermine Brunner², Jennifer Huggins³, Angela Merritt³, Megan Quilan-Waters³, Catherine Robben³, Chen Chen³, Daniel J Lovell⁴ and Bin Huang³, ¹Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Johns Hopkins University, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴UC Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, OH
Background/Purpose: Physician Global Assessment of Disease Activity (PhGA) are commonly used outcome measures in pediatric rheumatology. For childhood-onset systemic lupus erythematosus (cSLE), the traditional visual…
Abstract Number: 1705 • ACR Convergence 2023
Reduced DNASE1L3 Activity and Increased Anti-NET Protective Antibodies Contributes to Accumulation of Neutrophil Extracellular Traps in Pediatric SLE Patients
Betsy Barnes¹, Lydia Thomas², Jenna Battaglia Battaglia³, Kim Simpfendorfer³, Joyce Hui-Yuen⁴, Vinay Sharma⁵ and Bharati Matta⁶, ¹Northwell Health, Manhasset, NY, ²Northwell Health - Cohen Children's Medical Center, Lake Success, NY, ³Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ⁴North Shore LIJ Health System, Great Neck, NY, ⁵Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, India, ⁶The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY and Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, NY
Background/Purpose: Pediatric systemic lupus erythematosus (pSLE) is a multisystemic chronic autoimmune disease with high renal involvement. In SLE, neutrophil extracellular traps (NETs) are considered a…
Abstract Number: 2052 • ACR Convergence 2023
Risk Factors for Hospitalization for SARS-CoV-2 in Pediatric Patients with Rheumatic Diseases: A Systematic Review and Meta-analysis
Qianzi Zhao¹, Beth Wallace², Lawrence Jung³ and Tova Ronis⁴, ¹Trinity Health Ann Arbor, Ann Arbor, MI, ²Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ³Jung Medical, Cedar Falls, IA, ⁴Children's National Hospital, Chevy Chase, MD
Background/Purpose: Among adults who develop SARS-CoV-2 infection, those with rheumatic diseases (RDs) have similar hospitalization rates compared to those without RDs. Similar comparisons are lacking…
Abstract Number: 2478 • ACR Convergence 2023
Effect of Conventional and Biologic Disease-Modifying Anti-Rheumatic Drugs on the Antibody Response to Four Doses of COVID-19 mRNA Vaccines in Children with Autoimmune and Rheumatic Diseases
Janna Shapiro¹, Florence Choi², Amy Xu³, Trang Duong⁴, Anne-Claude Gingras⁵, Sasha Bernatsky⁶, Susanne (Susa) Benseler⁷ and Rae Yeung⁸, ¹University of Toronto, Toronto, ON, Canada, ²Hong Kong Hospital Authority, Hong Kong, Hong Kong, ³Division of Rheumatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital Sinai Health, Toronto, ON, Canada, ⁶Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Children with rheumatic and autoimmune diseases are often treated with conventional or biologic disease-modifying antirheumatic drugs (cDMARDs and bDMARDs) to control disease. While effective,…
Abstract Number: 007 • 2023 Pediatric Rheumatology Symposium
Single Cell RNA Sequencing Analysis of the Skin to Evaluate the Effect of Autologous Stem Cell Transplant on Fibroblast Populations in Juvenile Onset Systemic Sclerosis
Claire Cheng, Giffin Werner, Anwesha Sanyal and Kathryn Torok, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Juvenile systemic sclerosis (JSSc) is a rare autoimmune disease associated with high morbidity. Inflammatory driven multi-organ fibrosis is similar to adult-onset SSc, with 40%…
Abstract Number: 047 • 2023 Pediatric Rheumatology Symposium
Clinical Characteristics and Outcomes of North American Youth with Lupus Nephritis Requiring Dialysis Treated with Cyclophosphamide
Christine Wang¹, Rebecca Sadun², Wenru Zhou³, Kristen Miller³, Claire Palmer³, Stacy Ardoin⁴, Christine Bacha⁵, Emily Hause⁶, Joyce Hui-Yuen⁷, Nicole Ling⁸, Maria Pereira⁹, Meredith Riebschleger¹, Kelly Rouster-Stevens¹⁰, Aliese Sarkissian¹¹, Julia Shalen¹², William Soulsby¹³, Marinka Twilt¹⁴, Eveline Wu¹⁵, Laura Lewandowski¹⁶, Scott Wenderfer¹⁷ and Jennifer Cooper¹⁸, ¹University of Michigan, Ann Arbor, MI, ²Duke University, Durham, NC, ³University of Colorado, Denver, CO, ⁴Nationwide Children's Hospital, Columbus, OH, ⁵Akron Children's Hospital, Akron, OH, ⁶University of Minnesota, Minneapolis, MN, ⁷Cohen Children's Medical Center, Northwell Health, Lake Success, New York; Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ⁸UCSF, San Francisco, CA, ⁹Baylor College of Medicine, Houston, TX, ¹⁰Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ¹¹UNC- Chapel Hill, Durham, NC, ¹²Johns Hopkins University, Baltimore, MD, ¹³University of California, San Francisco, San Francisco, CA, ¹⁴Alberta Children's Hospital, Calgary, AB, Canada, ¹⁵UNC Chapel Hill, Chapel Hill, NC, ¹⁶NIAMS, NIH, Bethesda, MD, ¹⁷British Columbia Children's Hospital, Vancouver, BC, Canada, ¹⁸University of Colorado/Children's Hospital Colorado, Denver, CO
Background/Purpose: Few studies have evaluated the clinical characteristics and outcomes of youth with lupus nephritis (LN) treated with cyclophosphamide (CYC) who initially required kidney replacement…
Abstract Number: 080 • 2023 Pediatric Rheumatology Symposium
Analysis of Proteasomal Activity – a Potential Diagnostic Tool for Proteasome-associated Autoinflammatory Syndromes (PRAAS)
Yoel Levinsky¹, Oded Scheuerman², Rotem Tal³, Gil Amarilyo³ and Liora Harel³, ¹Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, ²Pediatric B department, Schneider children's medical center of Israel, Petach Tikva, Israel, ³Pediatric rheumatology clinic, Schneider children's medical center of Israel, Petach Tikva, Israel
Background/Purpose: Interferonopathies are a recently recognized group of genetic syndromes associated with uncontrolled activation of interferon. PRAAS (proteasome-associated autoinflammatory syndromes) is an interferonopathy caused by…
Abstract Number: 123 • 2023 Pediatric Rheumatology Symposium
Development of Specific Classification Criteria for Juvenile System Sclerosis Patients: A Scoping Review
Ioana Dobre¹, Suzanne Li², Natalia Vasquez Canizares³, Barbara Reich⁴, Xurong Zhao⁵, Quinn McCormick⁶ and Marinka Twilt⁵, ¹Alberta Children's Hospital/University of Calgary, Calgary, AB, Canada, ²Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, Hackensack, NJ, ³Children's Hospital at Montefiore, New York, NY, ⁴Hackensack University Medical Center, Hackensack, NJ, ⁵Alberta Children's Hospital, Calgary, AB, Canada, ⁶Hackensack Medical Hospital Network, Hackensack, NJ
Background/Purpose: Juvenile systemic sclerosis (jSSc) is associated with one of the highest morbidity and mortality rate in pediatric rheumatology, yet care recommendations are based upon…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].